December 4, 2018
Astellas Pharma rolled out on December 3 its FLT3 inhibitor Xospata Tablet 40 mg (gilteritinib) in Japan for the treatment of relapsed or refractory acute myeloid leukemia (AML) with FLT3 mutations. Xospata is believed to suppress the growth of mutant...read more